Robert W. Baird reaffirmed their buy rating on shares of Myovant Sciences Ltd (NASDAQ:MYOV) in a report released on Friday morning. Robert W. Baird currently has a $20.00 target price on the stock.

Other research analysts have also recently issued research reports about the company. Cowen and Company reiterated a buy rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. Zacks Investment Research upgraded Myovant Sciences from a sell rating to a hold rating in a research report on Thursday, September 7th. Evercore ISI began coverage on Myovant Sciences in a research report on Wednesday, August 16th. They set an outperform rating on the stock. Finally, JMP Securities reiterated an outperform rating and set a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $20.00.

Myovant Sciences (NASDAQ MYOV) traded up $0.01 during mid-day trading on Friday, reaching $14.21. The company’s stock had a trading volume of 14,510 shares, compared to its average volume of 36,788. Myovant Sciences has a 1 year low of $9.92 and a 1 year high of $18.85.

ILLEGAL ACTIVITY WARNING: “Myovant Sciences Ltd (MYOV) Given Buy Rating at Robert W. Baird” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2017/11/12/myovant-sciences-ltd-myov-given-buy-rating-at-robert-w-baird.html.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Myovant Sciences by 18.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock worth $1,382,000 after purchasing an additional 14,203 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth $648,000. RA Capital Management LLC grew its holdings in shares of Myovant Sciences by 19.6% during the 2nd quarter. RA Capital Management LLC now owns 2,807,550 shares of the company’s stock worth $32,848,000 after purchasing an additional 459,128 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Myovant Sciences during the 2nd quarter worth $174,000. Finally, Voya Investment Management LLC grew its holdings in shares of Myovant Sciences by 5.4% during the 2nd quarter. Voya Investment Management LLC now owns 421,397 shares of the company’s stock worth $4,931,000 after purchasing an additional 21,478 shares in the last quarter.

Myovant Sciences Company Profile

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Analyst Recommendations for Myovant Sciences (NASDAQ:MYOV)

Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.